Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 8/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.32 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6330589 | 1.00 | P2RX7 (0.34) | P2RX7MEN1ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL6327546 | 0.92 | P2RX7 (0.39) | P2RX7MEN1KMT2AL3MBTL1MAPK14 | |
| SCHEMBL6327540 | 0.92 | P2RX7 (0.39) | P2RX7MEN1KMT2AL3MBTL1MAPK14 | |
| SCHEMBL6333390 | 0.78 | MEN1 (0.44) | P2RX7MEN1ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL6333379 | 0.77 | P2RX7 (0.38) | P2RX7MEN1ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL6329598 | 0.72 | HTR2A (0.39) | P2RX7 | |
| SCHEMBL14542094 | 0.68 | L3MBTL1 (0.40) | MEN1ALDH1A1KMT2AL3MBTL1HSD11B1 | |
| SCHEMBL28026688 | 0.66 | L3MBTL1 (0.50) | MEN1KMT2AL3MBTL1 | |
| SCHEMBL6329615 | 0.66 | P2RX7 (0.37) | P2RX7 | |
| SCHEMBL1833474 | 0.66 | L3MBTL1 (0.42) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050085509-A1 | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO. LTD. (JP) | 2005-04-21 | — | — | US | claimed |
| EP-1447401-A1 | PIPERIDIN-2-ONE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-08-18 | — | — | EP | claimed |
| US-20050085509-A1 | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO. LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
| EP-1447401-A1 | PIPERIDIN-2-ONE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085509-A1 | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | MAPKAP1, MAPK1, MAPK8 | P2RX7 2638/4885MEN1 205/4885ALDH1A1 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.